By World Healthcare Journal-
The vaccine from Moderna has become the latest potential candidate to release their results from large scale phase III testing, indicating that the vaccine is nearly 95 per cent effective at preventing coronavirus infection.
This is the third vaccine to announce its efficacy rates and was co-created by Moderna and the NIAID (National Institute for Allergies & Infectious Diseases).
This follows announcements from Pfizer and the Russian vaccine, Sputnik V, that their vaccines are up to 90 per cent and 93 per cent effective respectively, making the Moderna vaccine the most effective so far.
"The overall effectiveness has been remarkable - it's a great day," Tal Zaks, CMO at Moderna, told the BBC.
Dr Stephen Hoge, President of Pfizer, also told the BBC that he "grinned ear to ear for a minute" when the testing results were officially announced.
"I don't think any of us really hoped that the vaccine would be 94% effective at preventing Covid-19 disease, that was really a stunning realisation."
Moderna has also announced that it plans to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation (EUA) in the coming weeks.
Another benefit of the Moderna vaccine is that it appears to be far easier to transport and store than the Pfizer vaccine, which needs to be stored at -80C and then thawed before injection.
Moderna has announced that it aims to manufacture as many as one billion doses next year. Nearly 770m doses have already been allocated, with the majority claimed by the US, who have agreed to buy an initial 100m doses with an option to buy as many as 400m.
UK Health Secretary Matt Hancock also announced this afternoon that the UK has agreed to buy 5m doses of the vaccine - however, he has made clear that that vaccine will likely not be available until next year.
#whjnews #whjvaccine #whjfabiansutch #coronavirus #whjamerica